Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models

Resistant Patient ◽

Xenograft Models ◽

Strong Antitumor Activity

Abstract 5609: ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, shows antitumor activity in gastric cancer patient-derived xenograft models with varying glypican-3 expression

10.1158/1538-7445.am2018-5609 ◽

2018 ◽

Cited By ~ 1

Author(s):

Azuma Yumiko ◽

Yuji Sano ◽

Toshiaki Tsunenari ◽

Yasuko Kinoshita ◽

Yoko Miyazaki ◽

...

Keyword(s):

Gastric Cancer ◽

T Cell ◽

Antitumor Activity ◽

Cancer Patient ◽

Gastric Cancer Patient ◽

Bispecific Antibody ◽

Xenograft Models ◽

Antibody Targeting

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

Journal of Experimental & Clinical Cancer Research ◽

10.1186/s13046-015-0243-5 ◽

2015 ◽

Vol 34 (1) ◽

Cited By ~ 22

Author(s):

Hung Huynh ◽

Richard Ong ◽

Dieter Zopf

Keyword(s):

Gastric Cancer ◽

Antitumor Activity ◽

Multikinase Inhibitor ◽

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0306 ◽

2011 ◽

Vol 10 (11) ◽

pp. 2200-2210 ◽

Cited By ~ 114

Author(s):

Genshi Zhao ◽

Wei-ying Li ◽

Daohong Chen ◽

James R. Henry ◽

Hong-Yu Li ◽

...

Keyword(s):

Growth Factor ◽

Antitumor Activity ◽

Fibroblast Growth Factor ◽

Broad Spectrum ◽

Growth Factor Receptors ◽

Selective Inhibitor ◽

Tumor Xenograft ◽

Fibroblast Growth ◽

Fibroblast Growth Factor Receptors ◽

Antitumor activity of MP0250, a bispecific VEGF- and HGF-targeting darpin, in patient-derived xenograft models.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.11039 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 11039-11039

Author(s):

Ulrike Fiedler ◽

Michael Tobias Stumpp ◽

Andreas Cornelius ◽

Savira Ekawardhani ◽

Keith Martin Dawson ◽

...

Keyword(s):

Antitumor Activity ◽

Abstract B134: The p38MAPK inhibitor LY2228820 dimesylate, in combination with cytotoxic agents, displays strong antitumor activity in human glioblastoma, multiple myeloma, and other mouse xenograft models.

10.1158/1535-7163.targ-11-b134 ◽

2011 ◽

Author(s):

Susan Pratt ◽

Robert Campbell ◽

Raymond Gilmour ◽

Nathan Brooks ◽

James Starling ◽

...

Keyword(s):

Multiple Myeloma ◽

Antitumor Activity ◽

Cytotoxic Agents ◽

Human Glioblastoma ◽

Mouse Xenograft ◽

Xenograft Models ◽

Strong Antitumor Activity

Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models

10.1158/1535-7163.targ-15-b100 ◽

2015 ◽

Cited By ~ 1

Author(s):

Scott K. Thompson ◽

Mahaboobi Jaleel ◽

Vijay Kumar Nyavanandi ◽

Murali Ramachandra ◽

Hosahalli Subramanya ◽

...

Keyword(s):

Antitumor Activity ◽

Xenograft Models ◽

Strong Antitumor Activity ◽

Selective Activity

Abstract B274: Discovery and characterization of a highly selective inhibitor of B-RAF, PI3K, and mTOR kinases with antitumor activity in B-RAF and B-RAF/PI3K pathway double mutant xenograft models.

10.1158/1535-7163.targ-13-b274 ◽

2013 ◽

Author(s):

Sanjeeva P. Reddy ◽

Mahaboobi Jaleel ◽

Vijay K. Nyavanandi ◽

Murali Ramachandra ◽

Hosahalli Subramanya ◽

...

Keyword(s):

Antitumor Activity ◽

Double Mutant ◽

Pi3k Pathway ◽

Selective Inhibitor ◽

Abstract 2951: Potent antisense pharmacology of highly optimized antisense oligonucleotides in multiple transgenic, spontaneous and patient derived xenograft models of cancer reveals antitumor activity for the non-coding RNA MALAT-1.

10.1158/1538-7445.am2012-2951 ◽

2012 ◽

Author(s):

Jeff Hsu ◽

Guobin He ◽

Gourab Bhattacharjee ◽

Tianyuan Zhou ◽

Chris May ◽

...

Keyword(s):

Antitumor Activity ◽

Antisense Oligonucleotides ◽

Non Coding Rna ◽

Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target

10.1158/1538-7445.am2015-2842 ◽

2015 ◽

Author(s):

Clemens Krepler ◽

Min Xiao ◽

Katrin Sproesser ◽

Patricia Brafford ◽

Batool Shannan ◽

...

Keyword(s):

Clinical Trials ◽

Combination Therapy ◽

Braf Inhibitor ◽

Second Line ◽

Resistant Patient ◽

Xenograft Models ◽

Therapy Target

Abstract 1230: BGB-283: a novel RAF Dimer inhibitor, displays potent antitumor activity in HCC patient derived xenograft models

10.1158/1538-7445.am2016-1230 ◽

2016 ◽

Author(s):

Zhiyu Tang ◽

Yong Liu ◽

Beibei Jiang ◽

Yajuan Gao ◽

Wenfeng Gong ◽

...

Keyword(s):

Antitumor Activity ◽